Goutham Sunny, AdvanTIG-202

Goutham Sunny: NEOPAN – Pancreatic Cancer Update in LAPC

Goutham Sunny, Resident Doctor at The Gujarat Cancer and Research Institute, posted on X:

“NEOPAN – Pancreatic Cancer Update In LAPC (locally advanced pancreatic cancer):

Trial compared FOLFIRINOX vs Gemcitabine

  • 171 patients, PS ≤1, unresectable cases.
  • Primary endpoint: PFS.
  • Secondary endpoints: OS, QoL, safety.

Results:

Median PFS:

  • FOLFIRINOX: 9.7 months.
  • Gemcitabine: 7.7 months.
  • HR = 0.7, P = .04.

Median OS:

  • FOLFIRINOX: 15.7 months.
  • Gemcitabine: 15.4 months.
  • HR = 1.02, P = .95.
  • Better PFS with FOLFIRINOX
  • No OS benefit
  • Well tolerated.”

Title: PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.

Authors: Michel Ducreux, Romain Desgrippes, Yves Rinaldi, Frédéric Di Fiore, Rosine Guimbaud, Ludovic Evesque, Jean-Baptiste Bachet, Pierre Vanelslander, Thierry Lecomte, Olivier Capitain, Aurélie Parzy, Marion Bolliet, Pierre-Luc Etienne, Julien Forestier, Farid El Hajbi, Anne-Laure Bignon, Valérie Lebrun-Ly, Nicolas De Sousa Carvalho, Matthieu Texier, Olivier Bouche

Read The Full Article at Journal of Clinical Oncology.

Goutham Sunny: NEOPAN - Pancreatic Cancer Update in LAPC

More posts featuring Goutham Sunny.

Anne-Laure Bignon Aurélie Parzy cancer Farid El Hajbi Frédéric Di Fiore Goutham Sunny Jean-Baptiste Bachet Julien Forestier Ludovic Evesque Marion Bolliet Matthieu Texier Michel Ducreux Nicolas De Sousa Carvalho Olivier Bouché Olivier Capitain OncoDaily Oncology Pancreatic Cancer Pierre Vanelslander Pierre-Luc Etienne Romain Desgrippes Rosine Guimbaud Thierry Lecomte Valérie Lebrun-Ly Yves Rinaldi